(RTTNews) - Nektar Therapeutics (NKTR) shares are rising more than 13 percent on Wednesday morning as the company entered into a clinical trial collaboration and supply agreement with Merck for a Phase 2/3 study of bempegaldesleukin Nektar's investigational IL-2 pathway agent, in combination with Merck's KEYTRUDA. The trial is intended for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck whose tumors express PD-L1. Currently, shares are at $25.49, up 13.49 percent from the previous close of $22.46. For the 52-week period, the shares have traded in a range of $13.63-$25.95 on a volume of 1,196,426.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
